AKER vs. ICCC, AWH, OCX, ABIO, CDIO, VNRX, TRIB, BMRA, TKNO, and CYTH
Should you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), ARCA biopharma (ABIO), Cardio Diagnostics (CDIO), VolitionRx (VNRX), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), and Cyclo Therapeutics (CYTH). These companies are all part of the "medical" sector.
Akers Biosciences (NASDAQ:AKER) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Akers Biosciences has higher earnings, but lower revenue than ImmuCell.
Akers Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
5.5% of Akers Biosciences shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 0.3% of Akers Biosciences shares are held by company insiders. Comparatively, 6.3% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, ImmuCell had 1 more articles in the media than Akers Biosciences. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Akers Biosciences. Akers Biosciences' average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.
Akers Biosciences has a net margin of 0.00% compared to ImmuCell's net margin of -33.05%. ImmuCell's return on equity of -21.79% beat Akers Biosciences' return on equity.
Akers Biosciences received 186 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 72.92% of users gave Akers Biosciences an outperform vote.
Summary
ImmuCell beats Akers Biosciences on 8 of the 12 factors compared between the two stocks.
Get Akers Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akers Biosciences Competitors List
Related Companies and Tools
